BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28149438)

  • 1. Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
    Iddrisah FN; Yeboah-Manu D; Nortey PA; Nyarko KM; Anim J; Antara SN; Kenu E; Wurapa F; Afari EA
    Pan Afr Med J; 2016; 25(Suppl 1):13. PubMed ID: 28149438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
    Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
    Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
    Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
    Adu EJ; Ampadu E
    Int J Mycobacteriol; 2015 Jun; 4(2):138-42. PubMed ID: 26972882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin.
    Yeboah-Manu D; Kpeli GS; Ruf MT; Asan-Ampah K; Quenin-Fosu K; Owusu-Mireku E; Paintsil A; Lamptey I; Anku B; Kwakye-Maclean C; Newman M; Pluschke G
    PLoS Negl Trop Dis; 2013; 7(5):e2191. PubMed ID: 23658847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a decentralized community-based treatment program to improve the management of Buruli ulcer in the Ouinhi district of Benin, West Africa.
    Amoussouhoui AS; Sopoh GE; Wadagni AC; Johnson RC; Aoulou P; Agbo IE; Houezo JG; Boyer M; Nichter M
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006291. PubMed ID: 29529087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
    Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
    Schütte D; Umboock A; Pluschke G
    Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
    Velink A; Woolley RJ; Phillips RO; Abass KM; van der Werf TS; Agumah E; de Zeeuw J; Klis S; Stienstra Y
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005261. PubMed ID: 28033343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
    Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo].
    Kibadi K
    Sante; 2007; 17(3):173-6. PubMed ID: 18180219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
    Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.
    Sopoh GE; Dossou AD; Brun LV; Barogui YT; Houézo JG; Affolabi D; Anagonou SY; Johnson RC; Kestens L; Portaels F
    Am J Trop Med Hyg; 2010 Aug; 83(2):307-13. PubMed ID: 20682873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.
    Tuffour J; Owusu-Mireku E; Ruf MT; Aboagye S; Kpeli G; Akuoku V; Pereko J; Paintsil A; Bonney K; Ampofo W; Pluschke G; Yeboah-Manu D
    Am J Trop Med Hyg; 2015 Aug; 93(2):216-23. PubMed ID: 26055745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.
    Amoako YA; Frimpong M; Awuah DO; Plange-Rhule G; Boakye-Yiadom E; Agbavor B; Sarpong F; Ahor H; Adu E; Danso KG; Abass MK; Asiedu K; Wansbrough-Jones M; Phillips RO
    J Med Case Rep; 2019 Jul; 13(1):218. PubMed ID: 31315637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buruli ulcer in West Africa: strategies for early detection and treatment in the antibiotic era.
    Webb BJ; Hauck FR; Houp E; Portaels F
    East Afr J Public Health; 2009 Aug; 6(2):144-7. PubMed ID: 20000019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.